COVID-19-associated cystitis (CAC) is a newly recognized urological condition characterized by genitourinary symptoms such as urinary urgency, frequency, nocturia, and pelvic discomfort, occurring after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. While overlapping with symptoms of overactive bladder (OAB), CAC appears to result from inflammatory, neurogenic, and possibly direct viral effects on the bladder urothelium, where ACE-2 receptors—key entry points for SARS-CoV-2—are significantly expressed. Initial definitions describe CAC as presenting with urinary frequency of ≥13 episodes/24 hours and nocturia ≥4 episodes/night. Diagnostic challenges stem from its symptom overlap with other conditions, the absence of specific biomarkers, and delayed symptom onset. Management focuses on symptomatic relief through existing therapies for OAB, including antimuscarinics, behavioral modifications, and pelvic floor exercises, with emerging interest in immunomodulatory agents and anti-inflammatory therapies. The long-term implications of CAC extend beyond physical symptoms, profoundly impacting mental health, social engagement, and occupational functioning. Current research underscores the need for standardized diagnostic criteria, targeted treatment approaches, and comprehensive care addressing the quality of life and psychosocial dimensions of affected patients. This entry synthesizes current knowledge on CAC’s pathophysiology, clinical presentation, diagnostic strategies, and management options, while highlighting gaps in understanding and avenues for future research to inform clinical practice and improve patient outcomes.